Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead

Bondeson, Daniel P., Smith, Blake E., Burslem, George M., Buhimschi, Alexandru D., Hines, John, Jaime-Figueroa, Saul, Wang, Jing, Hamman, Brian D. +2 more·2018·Cell Chemical Biology
DOI 10.1016/j.chembiol.2017.09.010

Cited by (965)

Items 101–200 of 965

  1. Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta
    Bai, Nan, Miller, Sven A., Andrianov, Grigorii V., Yates, Max, Kirubakaran, Palani, Karanicolas, John · 2021 · Journal of Chemical Information and Modeling
  2. Understanding and Improving the Membrane Permeability of VH032-Based PROTACs
    Victoria G. Klein, Chad E. Townsend, Andrea Testa, Michael Zengerle, Chiara Maniaci, Scott J. Hughes, Kwok-Ho Chan, Alessio Ciulli, R. Scott Lokey · 2020 · ACS Medicinal Chemistry Letters
  3. Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development
    Pan Tang, Jifa Zhang, Jie Liu, Cheng‐Ming Chiang, Liang Ouyang · 2021 · Journal of Medicinal Chemistry
  4. Mutant-selective degradation by BRAF-targeting PROTACs
    Alabi, Shanique, Jaime-Figueroa, Saul, Yao, Zhan, Gao, Yijun, Hines, John, Samarasinghe, Kusal T. G., Vogt, Lea, Rosen, Neal, Crews, Craig M. · 2021 · Nature Communications
  5. Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway
    Philipp Ottis, Chiara Palladino, Phillip Thienger, Adrian Britschgi, Christian Heichinger, Marco Berrera, Alice Julien-Laferrière, Filip Roudnicky, Tony Kam‐Thong, James Robert Bischoff et al. · 2019 · ACS Chemical Biology
  6. Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation
    Aimo Kannt, Ivan Đikić · 2021 · Cell chemical biology
  7. Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation
    Mengyang Chang, Feng Gao, Devin Pontigon, Giri Raj Gnawali, Hang Xu, Wei Wang · 2023 · Journal of the American Chemical Society
  8. The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination
    Jinmei Jin, Ye Wu, Jin‐Jiao Chen, Yiwen Shen, Lijun Zhang, Hong Zhang, Lili Chen, Hebao Yuan, Hongzhuan Chen, Weidong Zhang et al. · 2020 · Theranostics
  9. Characteristic roadmap of linker governs the rational design of PROTACs
    Dong, Yawen, Ma, Tingting, Xu, Ting, Feng, Zhangyan, Li, Yonggui, Song, Lingling, Yao, Xiaojun, Ashby, Charles R., Hao, Ge-Fei · 2024 · Acta Pharmaceutica Sinica B
  10. Amide-to-Ester Substitution as a Strategy for Optimizing PROTAC Permeability and Cellular Activity
    Klein, Victoria G., Bond, Adam G., Craigon, Conner, Lokey, R. Scott, Ciulli, Alessio · 2021 · Journal of Medicinal Chemistry
  11. Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions
    Popow, Johannes, Arnhof, Heribert, Bader, Gerd, Berger, Helmut, Ciulli, Alessio, Covini, David, Dank, Christian, Gmaschitz, Teresa, Greb, Peter, Karolyi-Özguer, Jale et al. · 2019 · Journal of Medicinal Chemistry
  12. A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
    Bery, Nicolas, Miller, Ami, Rabbitts, Terry · 2020 · Nature Communications
  13. Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
    Jan, Max, Sperling, Adam S., Ebert, Benjamin L. · 2021 · Nature Reviews Clinical Oncology
  14. Targeting IRAK4 for Degradation with PROTACs
    Nunes, Joao, McGonagle, Grant A., Eden, Jessica, Kiritharan, Girieshanie, Touzet, Megane, Lewell, Xiao, Emery, John, Eidam, Hilary, Harling, John D., Anderson, Niall A. · 2019 · ACS Medicinal Chemistry Letters
  15. Driving E3 Ligase Substrate Specificity for Targeted Protein Degradation: Lessons from Nature and the Laboratory
    Angus D. Cowan, Alessio Ciulli · 2022 · Annual Review of Biochemistry
  16. Targeted Degradation of a Hypoxia-Associated Non-coding RNA Enhances the Selectivity of a Small Molecule Interacting with RNA
    Matthew G. Costales, Blessy M. Suresh, Kamalakannan Vishnu, Matthew David Disney · 2019 · Cell chemical biology
  17. The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells
    Kurimchak, Alison M., Herrera-Montávez, Carlos, Montserrat-Sangrà, Sara, Araiza-Olivera, Daniela, Hu, Jianping, Neumann-Domer, Ryan, Kuruvilla, Mathew, Bellacosa, Alfonso, Testa, Joseph R., Jin, Jian et al. · 2022 · Science Signaling
  18. Targeted Protein Degradation by Electrophilic PROTACs that Stereoselectively and Site-Specifically Engage DCAF1
    Yongfeng Tao, David Remillard, Ekaterina V. Vinogradova, Minoru Yokoyama, Sofia Banchenko, David Schwefel, Bruno N. Melillo, Stuart L. Schreiber, Xiaoyu Zhang, Benjamin F. Cravatt · 2022 · Journal of the American Chemical Society
  19. Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel–Lindau (VHL) E3 Ubiquitin Ligase
    Zhao, Quanju, Ren, Chaowei, Liu, Linyi, Chen, Jinju, Shao, Yubao, Sun, Ning, Sun, Renhong, Kong, Ying, Ding, Xinyu, Zhang, Xianfang et al. · 2019 · Journal of Medicinal Chemistry
  20. Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins — A review
    Chao‐Yie Yang, Chong Qin, Longchuan Bai, Shaomeng Wang · 2019 · Drug Discovery Today Technologies
  21. Folate-Guided Protein Degradation by Immunomodulatory Imide Drug-Based Molecular Glues and Proteolysis Targeting Chimeras
    He Chen, Jing Liu, H. Ümit Kanıskan, Wenyi Wei, Jian Jun Jin · 2021 · Journal of Medicinal Chemistry
  22. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
    He, Yonghan, Khan, Sajid, Huo, Zhiguang, Lv, Dongwen, Zhang, Xuan, Liu, Xingui, Yuan, Yaxia, Hromas, Robert, Xu, Mingjiang, Zheng, Guangrong et al. · 2020 · Journal of Hematology & Oncology
  23. Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins
    Shirasaki, Ryosuke, Matthews, Geoffrey M., Gandolfi, Sara, de Matos Simoes, Ricardo, Buckley, Dennis L., Raja Vora, Joseline, Sievers, Quinlan L., Brüggenthies, Johanna B., Dashevsky, Olga, Poarch, Haley et al. · 2021 · Cell Reports
  24. Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1
    Binbin Cheng, Yichang Ren, Hao Cao, Jianjun Chen · 2020 · European Journal of Medicinal Chemistry
  25. Cellular senescence in lung cancer: Molecular mechanisms and therapeutic interventions
    Saurav Kumar Jha, Gabriele De Rubis, Shankar Raj Devkota, Yali Zhang, Radhika Adhikari, Laxmi Akhileshwar Jha, Kunal Bhattacharya, Samir Mehndiratta, Gaurav Gupta, Sachin Kumar Singh et al. · 2024 · Ageing Research Reviews
  26. PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes
    Smalley, Joshua P., Adams, Grace E., Millard, Christopher J., Song, Yun, Norris, James K. S., Schwabe, John W. R., Cowley, Shaun Michael, Hodgkinson, James T. · 2020 · Chemical Communications
  27. Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies
    DANIEL W. ROBBINS, Mark Noviski, Ying Siow Tan, Zef A. Könst, Aileen Kelly, Paul Auger, Nivetha Brathaban, Robert T. Cass, Ming Liang Chan, Ganesh Cherala et al. · 2024 · Journal of Medicinal Chemistry
  28. Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)
    Dragovich, Peter S., Adhikari, Pragya, Blake, Robert A., Blaquiere, Nicole, Chen, Jinhua, Cheng, Yun-Xing, den Besten, Willem, Han, Jinping, Hartman, Steven J., He, Jintang et al. · 2020 · Bioorganic & Medicinal Chemistry Letters
  29. Bivalent Ligands for Protein Degradation in Drug Discovery
    Marcel Scheepstra, Koen F. W. Hekking, Luc Van Hijfte, Rutger H. A. Folmer · 2019 · Computational and Structural Biotechnology Journal
  30. Strategies for designing proteolysis targeting chimaeras (PROTACs)
    Shipeng He, Guoqiang Dong, Junfei Cheng, Ying Wu, Chunquan Sheng · 2022 · Medicinal Research Reviews
  31. Development of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins
    Nobumichi Ohoka, Genichiro Tsuji, Takuji Shoda, Takuma Fujisato, Masaaki Kurihara, Yosuke Demizu, Mikihiko Naito · 2019 · ACS Chemical Biology
  32. A bibliometric analysis of PROTAC from 2001 to 2021
    Deping Li, Dongmin Yu, Yan Li, Renze Yang · 2022 · European Journal of Medicinal Chemistry
  33. Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1/Bcl-2 Derived from Nonselective Target Binding Ligands
    Wang, Ziqian, He, Nianzhe, Guo, Zongwei, Niu, Cuili, Song, Ting, Guo, Yafei, Cao, Keke, Wang, Anhui, Zhu, Junjie, Zhang, Xiaodong et al. · 2019 · Journal of Medicinal Chemistry
  34. A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL
    Tong, Bingqi, Spradlin, Jessica N., Novaes, Luiz F. T., Zhang, Erika, Hu, Xirui, Moeller, Malte, Brittain, Scott M., McGregor, Lynn M., McKenna, Jeffrey M., Tallarico, John A. et al. · 2020 · ACS Chemical Biology
  35. Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1
    Mingxing Hu, Weilin Zhou, Yijie Wang, Dongping Yao, Tinghong Ye, Yuqin Yao, Bin Chen, Gong‐Ping Liu, Xifei Yang, Wei Wang et al. · 2020 · Acta Pharmaceutica Sinica B
  36. Large-scale discovery of male reproductive tract-specific genes through analysis of RNA-seq datasets
    Matthew J. Robertson, Katarzyna Kent, Nathan Tharp, Kaori Nozawa, Laura Dean, Michelle Mathew, Sandra L. Grimm, Zhifeng Yu, Christine Légaré, Yoshitaka Fujihara et al. · 2020 · BMC Biology
  37. Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes
    Ingo Volker Hartung, Joachim Rudolph, Mary M. Mader, Monique P. C. Mulder, Paul Workman · 2023 · Journal of Medicinal Chemistry
  38. Delivering on the promise of protein degraders
    Matthew N. O’Brien, Suman A. Luthra, Matthew F. Brown, Derek W. Bartlett · 2023 · Nature Reviews Drug Discovery
  39. PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies
    Nuwayo Ishimwe Sincere, Krishnan Anand, Sumel Ashique, Jing Yang, Chongge You · 2023 · Molecules
  40. Development and Characterization of a Wee1 Kinase Degrader
    Zhengnian Li, Benika J. Pinch, Calla M. Olson, Katherine A. Donovan, Radosław P. Nowak, Caitlin E. Mills, David A. Scott, Zainab M. Doctor, Nicholas A. Eleuteri, Mirra Chung et al. · 2019 · Cell chemical biology
  41. Design and synthesis of selective degraders of EGFRL858R/T790M mutant
    Xin Zhang, Fang Xu, Linjiang Tong, Tao Zhang, Hua Xie, Xiaoyun Lu, Xiaomei Ren, Ke Ding · 2020 · European Journal of Medicinal Chemistry
  42. Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK)
    Yang Lu, Haiying Sun · 2020 · Journal of Medicinal Chemistry
  43. The importance of cellular degradation kinetics for understanding mechanisms in targeted protein degradation
    Kristin M. Riching, Elizabeth A. Caine, Marjeta Urh, Danette L. Daniels · 2022 · Chemical Society Reviews
  44. Targeted protein degradation directly engaging lysosomes or proteasomes
    Jiseong Kim, Insuk Byun, Do Young Kim, Hyunhi Joh, Hak Joong Kim, Min Jae Lee · 2024 · Chemical Society Reviews
  45. Mechanistic and Structural Features of PROTAC Ternary Complexes
    Ryan Casement, Adam G. Bond, Conner Craigon, Alessio Ciulli · 2021 · Methods in molecular biology
  46. Cereblon modulators: Low molecular weight inducers of protein degradation
    Chamberlain, Philip P., Cathers, Brian E. · 2019 · Drug Discovery Today: Technologies
  47. The ubiquitin codes in cellular stress responses
    Xiangpeng Sheng, Zhixiong Xia, Hanting Yang, Ronggui Hu · 2023 · Protein & Cell
  48. Chromatin remodellers as therapeutic targets
    Hayden A. Malone, Charles W.M. Roberts · 2024 · Nature Reviews Drug Discovery
  49. Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma
    Yalin Tu, Yameng Sun, Shuang Qiao, Yao Luo, Panpan Liu, Zhong‐Xing Jiang, Yumin Hu, Zifeng Wang, Peng Huang, Shijun Wen · 2021 · Journal of Medicinal Chemistry
  50. Indomethacin-based PROTACs as pan-coronavirus antiviral agents
    Jenny Desantis, Beatrice Mercorelli, Marta Celegato, Federico Croci, Alessandro Bazzacco, Massimo Baroni, Lydia Siragusa, Gabriele Cruciani, Arianna Loregian, Laura Goracci · 2021 · European Journal of Medicinal Chemistry
  51. Bifunctional chemical probes inducing protein–protein interactions
    Maniaci, Chiara, Ciulli, Alessio · 2019 · Current Opinion in Chemical Biology
  52. Predicting the structural basis of targeted protein degradation by integrating molecular dynamics simulations with structural mass spectrometry
    Tom J. Dixon, Derek J. MacPherson, Barmak Mostofian, T. A. Dauzhenka, Samuel Lotz, T. Dwight McGee, Sharon Shechter, Utsab R. Shrestha, Rafal Wiewiora, Zachary A. McDargh et al. · 2022 · Nature Communications
  53. Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
    Bhawana George, Sayan Mullick Chowdhury, Amber Hart, Anuvrat Sircar, Satish Kumar Singh, Uttam Kumar Nath, Mukesh Mamgain, Naveen Kumar Singhal, Lalit Sehgal, Neeraj Kumar Jain · 2020 · Cancers
  54. PROTAC degraders as chemical probes for studying target biology and target validation
    Němec, Václav, Schwalm, Martin P., Müller, Susanne, Knapp, Stefan · 2022 · Chemical Society Reviews
  55. Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality
    Milka Kostić, Lyn H. Jones · 2020 · Trends in Pharmacological Sciences
  56. Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy
    Geun Taek Lee, Naoya Nagaya, Jenny Desantis, Kiran Madura, Hatem E. Sabaawy, Wun-Jae Kim, Roy J. Vaz, Gabriele Cruciani, Isaac Yi Kim · 2020 · Molecular Cancer Therapeutics
  57. Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader
    Hannah Tovell, Andrea Testa, Houjiang Zhou, Natalia Shpiro, Claire Crafter, Alessio Ciulli, Dario R. Alessi · 2019 · ACS Chemical Biology
  58. Photopharmacology and photoresponsive drug delivery
    Yuwei Liu, Tianyi Wang, Weiping Wang · 2025 · Chemical Society Reviews
  59. Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC)
    Fangyuan Cao, Sander de Weerd, Deng Chen, Martijn R. H. Zwinderman, Petra E. van der Wouden, Frank J. Dekker · 2020 · European Journal of Medicinal Chemistry
  60. Chemo-proteomics exploration of HDAC degradability by small molecule degraders
    Yuan Xiong, Katherine A. Donovan, Nicholas A. Eleuteri, Nadia Kirmani, Hong Yue, Anthony Razov, Noah M. Krupnick, Radosław P. Nowak, Eric S. Fischer · 2021 · Cell chemical biology
  61. Molecular Strategies to Target Protein Aggregation in Huntington’s Disease
    Olga D. Jarosińska, Stefan Rüdiger · 2021 · Frontiers in Molecular Biosciences
  62. Expanding the role of proteasome homeostasis in Parkinson’s disease: beyond protein breakdown
    Mingxia Bi, Xixun Du, Qian Jiao, Xi Chen, Hong Fu Jiang · 2021 · Cell Death and Disease
  63. Assessing the Cell Permeability of Bivalent Chemical Degraders Using the Chloroalkane Penetration Assay
    Foley, Caroline A., Potjewyd, Frances, Lamb, Kelsey N., James, Lindsey I., Frye, Stephen V. · 2020 · ACS Chemical Biology
  64. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties
    Jaime-Figueroa, Saul, Buhimschi, Alexandru D., Toure, Momar, Hines, John, Crews, Craig M. · 2020 · Bioorganic & Medicinal Chemistry Letters
  65. Proteolysis targeting chimeras (PROTACs) in cancer therapy
    Alberto Ocaña, Atanasio Pandiella · 2020 · Journal of Experimental & Clinical Cancer Research
  66. Stimuli-activatable PROTACs for precise protein degradation and cancer therapy
    Jing Gao, Lei Yang, Shumin Lei, Feng Zhou, Hui‐Jun Nie, Bo Peng, Tianfeng Xu, Xiaohua Chen, Xiaobao Yang, Chunquan Sheng et al. · 2023 · 中国科学通报：英文版
  67. Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease
    Yugendar R. Alugubelli, Jing Xiao, Kaustav Khatua, Sathish Kumar, Long Sun, Yuying Ma, Xinyu R. Ma, Veerabhadra R. Vulupala, Sandeep Atla, Lauren R. Blankenship et al. · 2024 · Journal of Medicinal Chemistry
  68. PROTACs and Other Chemical Protein Degradation Technologies for the Treatment of Neurodegenerative Disorders
    Shusuke Tomoshige, Minoru Ishikawa · 2020 · Angewandte Chemie International Edition
  69. Development of CDK2 and CDK5 Dual Degrader TMX‐2172
    Mingxing Teng, Jie Jiang, Zhixiang He, Nicholas P. Kwiatkowski, Katherine A. Donovan, Caitlin E. Mills, Chiara Victor, John M. Hatcher, Eric S. Fischer, Peter Karl Sorger et al. · 2020 · Angewandte Chemie International Edition
  70. An up-to-date overview of computational polypharmacology in modern drug discovery
    Rajan R. Chaudhari, Lon Wolf R. Fong, Zhi Tan, Beibei Huang, Shuxing Zhang · 2020 · Expert Opinion on Drug Discovery
  71. Optimal linker length for small molecule PROTACs that selectively target p38α and p38β for degradation
    Craig Donoghue, Monica Cubillos‐Rojas, Nuria Martí Gutiérrez, Carolina Sánchez, Xavier Verdaguer, Antoni Riéra, Ángel R. Nebreda · 2020 · European Journal of Medicinal Chemistry
  72. The rise and rise of protein degradation: Opportunities and challenges ahead
    Scott J. Hughes, Andrea Testa, Nicola Thompson, Ian Churcher · 2021 · Drug Discovery Today
  73. Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies
    Xiaopeng Peng, Zhihao Hu, Limei Zeng, Meizhu Zhang, Congcong Xu, Benyan Lu, Chengpeng Tao, Wei‐Ming Chen, Wen Hou, Kui Cheng et al. · 2023 · Acta Pharmaceutica Sinica B
  74. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras
    Yingming Wang, Lingfei Han, Fulei Liu, Fubai Yang, Xueyang Jiang, Haopeng Sun, Feng Feng, Jingwei Xue, Wenyuan Liu · 2020 · Colloids and Surfaces B Biointerfaces
  75. A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders
    Ka Yang, Yu Zhao, Xueqing Nie, Hao Wu, Bo Wang, Chelsi M. Almodóvar‐Rivera, Haibo Xie, Weiping Tang · 2020 · Cell chemical biology
  76. Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK)
    Shaowen Xie, Yuan Sun, Yulin Liu, Xinnan Li, Xinuo Li, Wenyi Zhong, Feiyan Zhan, Jingjie Zhu, Hong Yao, Dong‐Hua Yang et al. · 2021 · Journal of Medicinal Chemistry
  77. Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras
    Akshay D. Takwale, Seung-Hyun Jo, Yeong Uk Jeon, Hyung Soo Kim, Choong Hoon Shin, Heung Kyoung Lee, Sunjoo Ahn, Chong Ock Lee, Jae Du Ha, Jeong‐Hoon Kim et al. · 2020 · European Journal of Medicinal Chemistry
  78. Mechanism of degrader-targeted protein ubiquitinability
    Charlotte Crowe, Mark A. Nakasone, Sarah Chandler, Conner Craigon, Gajanan J. Sathe, Michael H. Tatham, Nikolai Makukhin, Ronald T. Hay, Alessio Ciulli · 2024 · Science Advances
  79. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs
    Bai, Nan, Riching, Kristin M., Makaju, Aman, Wu, Hao, Acker, Timothy M., Ou, Shu-Ching, Zhang, Yaru, Shen, Xiaomeng, Bulloch, Daryl N., Rui, Huan et al. · 2022 · Journal of Biological Chemistry
  80. Molecular mechanisms of cereblon-based drugs
    Tomoko Asatsuma‐Okumura, Takumi Ito, Hiroshi Handa · 2019 · Pharmacology & Therapeutics
  81. HDAC Inhibitors: Innovative Strategies for Their Design and Applications
    Mateusz Daśko, Beatriz de Pascual‐Teresa, Irene Ortín, Ana Ramos · 2022 · Molecules
  82. HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations
    Yong Du, Yongfeng Chen, Yuxia Wang, Jinju Chen, Xiaorong Lu, Li Zhang, Yan Li, Zhaofu Wang, Guozhong Ye, George Zhang · 2022 · Molecular Cancer Therapeutics
  83. PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer
    Kailee A. Rutherford, Kirk James McManus · 2024 · Molecular Cancer Therapeutics
  84. Advancing Strategies for Proteolysis-Targeting Chimera Design
    Minglei Li, Ying Zhi, Bo Liu, Qingqiang Yao · 2023 · Journal of Medicinal Chemistry
  85. New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives
    Viola Previtali, Greta Bagnolini, Andrea Ciamarone, Giovanni Ferrandi, Francesco Rinaldi, Samuel Harry Myers, Marinella Roberti, Andrea Cavalli · 2024 · Journal of Medicinal Chemistry
  86. Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy
    Shi Shi, Yu Du, Lei Haley Huang, Jiaqi Cui, Jing Niu, Yungen Xu, Qihua Zhu · 2022 · Bioorganic Chemistry
  87. Hi-JAK-ing the ubiquitin system: The design and physicochemical optimisation of JAK PROTACs
    Rishi R. Shah, Joanna M. Redmond, Andrei Mihut, Malini R. Menon, John P. Evans, John Anthony Murphy, Michelle A. Bartholomew, Diane M. Coe · 2020 · Bioorganic & Medicinal Chemistry
  88. Optical control of targeted protein degradation
    Martin Reynders, Dirk H. Trauner · 2021 · Cell chemical biology
  89. High-potency PD-1/PD-L1 degradation induced by Peptide-PROTAC in human cancer cells
    Mengyuan Dai, Yuying Shi, An-Jin Wang, Xuelian Liu, Miao Liu, Hongbing Cai · 2022 · Cell Death and Disease
  90. A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo
    Atsunori Kaneshige, Longchuan Bai, Mi Wang, Donna McEachern, Jennifer L. Meagher, Renqi Xu, Yu Wang, Wei Jiang, Hoda Metwally, Paul D. Kirchhoff et al. · 2023 · Nature Chemical Biology
  91. Integrated Direct-to-Biology Platform for the Nanoscale Synthesis and Biological Evaluation of PROTACs
    Rebecca Stevens, Enrique Bendito-Moll, David J. Battersby, Afjal H. Miah, Natalie Wellaway, Robert P. Law, Peter Stacey, Diana Klimaszewska, Justyna M. Macina, Glenn A. Burley et al. · 2023 · Journal of Medicinal Chemistry
  92. Assays and Technologies for Developing Proteolysis Targeting Chimera Degraders
    Xingui Liu, Xuan Zhang, Dongwen Lv, Yaxia Yuan, Guangrong Zheng, Daohong Zhou · 2020 · Future Medicinal Chemistry
  93. A novel cereblon modulator for targeted protein degradation
    Kim, Sung Ah, Go, Ara, Jo, Seung-Hyun, Park, Sun Jun, Jeon, Young Uk, Kim, Ji Eun, Lee, Heung Kyoung, Park, Chi Hoon, Lee, Chong-Ock, Park, Sung Goo et al. · 2019 · European Journal of Medicinal Chemistry
  94. Inducing protein-protein interactions with molecular glues
    Ye Che, Adam M. Gilbert, Veerabahu Shanmugasundaram, Mark C. Noe · 2018 · Bioorganic & Medicinal Chemistry Letters
  95. The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods
    Antonio Curcio, Roberta Rocca, Stefano Alcaro, Anna Artese · 2024 · Pharmaceuticals
  96. The rise of covalent proteolysis targeting chimeras
    Ronen Gabizon, Nir London · 2021 · Current Opinion in Chemical Biology
  97. Nuclear localisation of Aurora-A: its regulation and significance for Aurora-A functions in cancer
    Francesco Davide Naso, Dalila Boi, Camilla Ascanelli, Georgiana Pamfil, Catherine Lindon, Alessandro Paiardini, Giulia Guarguaglini · 2021 · Oncogene
  98. Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review
    Mostafa A. Mansour, Asmaa M. AboulMagd, Samar H. Abbas, Hamdy Mohamed Abdel-Rahman, Mohamed Abdel‐Aziz · 2023 · RSC Advances
  99. VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives
    Chao Wang, Yujing Zhang, Jie Wang, Dongming Xing · 2021 · European Journal of Medicinal Chemistry
  100. Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong in vivo Antitumor Activity
    Lin Yang, Wenbin Tu, Liyue Huang, Bukeyan Miao, Atsunori Kaneshige, Wei Jiang, Lingying Leng, Meilin Wang, Bo Wen, Duxin Sun et al. · 2023 · Journal of Medicinal Chemistry